
## Frederico Teixeira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3641241/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovascular Diabetology, 2011, 10, 12.	6.8	198
2	Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta, 2001, 303, 33-39.	1.1	182
3	Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators of Inflammation, 2010, 2010, 1-11.	3.0	143
4	Peloids and pelotherapy: Historical evolution, classification and glossary. Applied Clay Science, 2013, 75-76, 28-38.	5.2	131
5	Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat). Experimental Diabetes Research, 2011, 2011, 1-12.	3.8	128
6	Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals. Mediators of Inflammation, 2014, 2014, 1-15.	3.0	97
7	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too―or "the Special One―Antidiabetic Class?. Journal of Diabetes Research, 2015, 2015, 1-28.	2.3	65
8	Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiology and Drug Safety, 2005, 14, 885-890.	1.9	59
9	Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovascular Diabetology, 2013, 12, 61.	6.8	56
10	New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging. Disease Markers, 2013, 34, 341-348.	1.3	56
11	Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. Journal of Dermatological Science, 2009, 55, 202-204.	1.9	53
12	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	1.4	41
13	Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type) Tj ETQq1 1	0.784314 1.1	4 rgBT /Over
14	Differential Effects of Acute (Extenuating) and Chronic (Training) Exercise on Inflammation and Oxidative Stress Status in an Animal Model of Type 2 Diabetes Mellitus. Mediators of Inflammation, 2011, 2011, 1-8.	3.0	38
15	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 677-683.	3.1	36
16	Psoriasis Therapy and Cardiovascular Risk Factors. American Journal of Clinical Dermatology, 2010, 11, 423-432.	6.7	36
17	Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations. Disease Markers, 2013, 35, 85-96.	1.3	32
18	Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties. International Journal of Molecular Sciences, 2012, 13, 8482-8499.	4.1	28

FREDERICO TEIXEIRA

#	Article	lF	CITATIONS
19	New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Disease Markers, 2013, 34, 341-8.	1.3	27
20	Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. International Journal of Molecular Sciences, 2014, 15, 8979-8997.	4.1	26
21	Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetology and Metabolic Syndrome, 2014, 6, 42.	2.7	23
22	Erythropoietin Promotes Deleterious Cardiovascular Effects and Mortality Risk in a Rat Model of Chronic Sports Doping. Cardiovascular Toxicology, 2009, 9, 201-210.	2.7	22
23	Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer. BioMed Research International, 2013, 2013, 1-11.	1.9	22
24	Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin. Mediators of Inflammation, 2013, 2013, 1-12.	3.0	21
25	Effect of Cyclosporin A on Rat Smooth-Muscle Cell Proliferation. Journal of Cardiovascular Pharmacology, 1998, 31, 46-49.	1.9	21
26	Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biology and Therapy, 2009, 8, 1615-1622.	3.4	19
27	The triglyceride lowering effect of fish oils is affected by fish consumption. International Journal of Cardiology, 1996, 57, 75-80.	1.7	18
28	Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients. American Journal of Clinical Dermatology, 2012, 13, 37-47.	6.7	15
29	Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sciences, 2005, 77, 2514-2528.	4.3	14
30	Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU International, 2011, 107, 135-143.	2.5	14
31	The Peripheral Serotonergic System and Platelet Aggregation in Cyclosporin A-Induced Hypertensive Rats. Thrombosis Research, 1999, 96, 365-372.	1.7	12
32	Cardiovascular effects of cyclosporin treatment in an experimental model. Revista Portuguesa De Cardiologia, 2002, 21, 141-55.	0.5	12
33	Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model. Mediators of Inflammation, 2010, 2010, 1-11.	3.0	11
34	Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Renal Failure, 2010, 32, 1073-1080.	2.1	10
35	Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers. BioMed Research International, 2014, 2014, 1-17.	1.9	9
36	Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide–cyclic guanosine-3′,5′-monophosphate disturbances. Thrombosis Research, 2003, 110, 107-115.	1.7	8

FREDERICO TEIXEIRA

#	Article	IF	CITATIONS
37	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. Scientific World Journal, The, 2013, 2013, 1-16.	2.1	7
38	Impairment of vascular and platelet levels of nitric oxide and cyclic guanosine-3',5'-monophosphate in cyclosporin A-induced hypertensive rats. Fundamental and Clinical Pharmacology, 2003, 17, 43-50.	1.9	6
39	Health-related quality of life in Portuguese psoriatic patients: Relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment. Journal of Dermatology, 2011, 38, 816-819.	1.2	6
40	Incisional hernia at the insertion site of the laparoscopic trocar: case report and review of the literature. Revista Do Hospital Das Clinicas, 2003, 58, 219-222.	0.5	6
41	Platelet Hyperactivation in Maintained Growth Hormone-Deficient Childhood Patients after Therapy Withdrawal as a Putative Earlier Marker of Increased Cardiovascular Risk. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 98-105.	3.6	5
42	Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model. Journal of Pharmacology and Pharmacotherapeutics, 2012, 3, 143-8.	0.4	5
43	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 2008, 120, 11-13.	1.4	4
44	Letter to the Editor: A potential mechanism for the pathogenesis of psoriasis <i>vulgaris</i> . International Journal of Dermatology, 2013, 52, 1429-1432.	1.0	0